# β2M Post-HD Rebound Prediction

> **NCT07713680** · — · RECRUITING · sponsor: **East and North Hertfordshire NHS Trust** · enrollment: 30 (estimated)

## Conditions studied

- Renal Disease, End Stage

## Interventions

- **DIAGNOSTIC_TEST:** β2-microglobulin blood concentration in mg/L

## Key facts

- **NCT ID:** NCT07713680
- **Lead sponsor:** East and North Hertfordshire NHS Trust
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-24
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07713680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07713680, "β2M Post-HD Rebound Prediction". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07713680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*